Celyad SA
Research Celyad SA (CYAD) on Bullrun: market cap EUR 17.60M, P/E 11.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCYAD
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 17.60M
- P/E11.8
- Financial periodFY2025
- RevenueEUR 21.00K
- Revenue growth-88.7%
- Net incomeEUR 830.00K
- Free cash flow-EUR 6.90M
- Gross margin61.9%
Valuation Snapshot
latest market cap is EUR 17.60M; P/E is 11.8.
Peer valuation comparison
Latest P/E is 11.75x versus a Healthcare sector median of 24.61x (52.3% below).
Latest P/E is 11.75x versus a Belgium median of 12.53x (6.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 21.00K | EUR 830.00K | -EUR 6.90M | 61.9% | 0.02 | EUR 1.71M | EUR 0 | EUR 2.44M |
| FY2024 | EUR 186.00K | -EUR 5.82M | -EUR 5.80M | 93.0% | -0.14 | EUR 4.20M | EUR 905.00K | EUR 512.00K |
| FY2023 | EUR 102.00K | -EUR 8.45M | -EUR 16.14M | 32.4% | -0.34 | EUR 7.00M | EUR 1.06M | EUR 6.30M |
| FY2022 | EUR 0 | -EUR 40.94M | -EUR 28.13M | n/a | -1.81 | EUR 12.45M | EUR 255.00K | EUR 4.32M |
| FY2021 | EUR 0 | -EUR 26.51M | -EUR 26.97M | n/a | n/a | EUR 30.02M | EUR 0 | EUR 30.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | EUR 17.60M | 11.8 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Celyad SA's market cap?
Celyad SA's market capitalization is EUR 17.60M.
What is Celyad SA's P/E ratio?
Celyad SA's price-to-earnings (P/E) ratio is 11.8.
What does Celyad SA do?
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.